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Abstract 
The primary objective of the study is to assemble population pharmacokinetic models 
from the cancer pharmacokinetics literature for different types of anti-cancer drugs and to 
formulate them in ways suitable for input into cancer simulation programs.  
       To fulfill the objectives, a step-based approach is adopted:  
1) To catalogue the types of pharmacokinetic models through general review articles 
and books  
2) To develop a search strategy for defining a body of research literature related to 
cancer pharmacokinetics in clinical trials for a limited set of drugs (Taxol, Platinum 
compounds. Fluoropyrimidine and Topoisomerase inhibitors)  
3) To collect pharmacokinetic articles according to defined search criteria 
4) To gather information from the collected PK articles  
5) To synthesize the information separately for each drug, using a questionnaire 
instrument and present them in template form for each class of antineoplastic agent. 
6) To formulate population pharmacokinetic models for each anti-cancer drug, from the 
constituent submodels for components of the overall model. 
This work will promote public health, specifically in support of the development of anti-
cancer drug regimens for cancer patients, by providing standardized information about 
pharmacokinetics for input into simulations. 
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1. INTRODUCTION 
An objective of clinical studies is to assess whether a drug candidate will be effective 
in the treatment of disease or condition and benefit/risk assessment with pre-existing 
drugs for treatment. Pharmacokinetic information collected during clinical trials helps 
physicians and pharmacists to use the drug to the best advantage for potential patients, 
thereby maximizing the benefit of the drug and minimizing the risk to the patient. The 
benefit would be immense if we could quantitate and predict the dose-concentration-
effect relationship with possible variations in the subpopulations. We have the choice of 
altering the dose and/or dosage intervals to enhance the chance of successful trial. Hence 
choosing the right dose and dosage interval is the major advantage of incorporating 
pharmacokinetics into the decision-making process for clinical drug development. In 
addition to this, the recent trend is in identifying sources of variability in pharmacokinetic 
parameters to determine the right dosage regimen for certain patient subpopulations or 
dose individualization, especially drugs with narrow therapeutic index. Thus the major 
contribution of pharmacokinetics is dosage regimen selection and adjustment for 
individual patients. 
Application of pharmacokinetics from drug development perspective 
Drug development relies significantly on acquiring knowledge of 
pharmacokinetics for a new drug entity. This is based on the hypothesis that the clinical 
effect takes place with a particular plasma concentration for a specific time period to 
reach the target site. Thus selecting the right dosage regimen takes place in stages Phase I 
– III. 
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Phase I 
The purpose of phase I is to determine the safety of the drug candidate. These 
trials rely on preclinical information and aims at safety assessment, determination of 
maximum tolerated dose and whether the drug has desirable pharmacokinetic properties. 
Phase II 
After safety assessment and assuming the safety of the drug is established in 
phase I, the drug candidate will proceed to phase II.  
“Phase II studies are sometimes categorized as phase IIa or phase IIb depending 
on their goals: 
To prove the drug “works” in patients (phase IIa) 
To determine the best dose, dose range, titration scheme, and dose interval (phase 
IIb) 1”. 
Phase III 
Phase III studies are conducted on larger patient population compared to phase II to 
provide statistical power to reject the null hypothesis of no treatment effect. If treatment 
is proved efficacious, it is based on the assumption that randomization has removed the 
bias in the form of confounding factors. The results of these pivotal trials are the primary 
factor in proving potential drug candidate to be approved by the Food and Drug 
Administration (FDA) and move on to the marketing phase. The focus shifts to 
characterizing the remaining unknown sources of pharmacokinetic variability to identify 
subpopulation of patients who may have special risks or require dosage regimen 
adjustments. This is achieved by population pharmacokinetics or by initiation of small, 
focused pharmacokinetic studies in special populations. 
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 2. BACKGROUND AND LITERATURE REVIEW 
2.1. Pharmacokinetics 
Pharmacokinetic processes are classified as absorption, distribution, metabolism 
and excretion (ADME). Each pharmacokinetic processes comprises of two components: 
1. Kinetic component and 2.Extent component 
Kinetic component 
Kinetic component refers to the rate of movement or how fast the process occurs 
over time1.  The basic pharmacokinetics issue about a drug disposition is whether it 
undergoes linear or nonlinear pharmacokinetics.  
Linear pharmacokinetics is defined from the differential equations that express the 
change in the amount or concentration of drug over time1. 
            Ck
dt
dC
el ×−=   
kel is the first-order rate constant for elimination out of the body. In the above 
equation, linear refers to the fact that the rate is directly proportional to concentration. 
Nonlinear applies to rate equations in which the rate is no longer linearly related to 
concentration. In pharmacokinetics this often applies to drugs for which metabolic 
pathways or plasma protein binding become saturated at concentrations usually within 
the therapeutic range1. 
Nonlinearity scenarios 
Area under the curve (AUC) is a parameter which gives an indication of systemic 
exposure and if there is disproportionate increase in AUC with dose escalation is an 
indication of nonlinear pharmacokinetics. Nonlinearity can be found using the plot AUC 
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vs. dose and AUC gets affected, perhaps by decrease/increase in clearance or 
decrease/increase in bioavailability or both.  
• Nonlinearity can occur due to one of the following reasons: 
• Saturation of metabolic pathway 
• Saturation of plasma binding site 
• Dose dependency 
• Time dependency 
• Affinity to the same binding site by concomitant drugs 
• Drug-drug interaction  
Extent component 
The extent component refers to the amount of drug or fraction of the dose that is 
absorbed, distributed, metabolized or excreted1 and described by pharmacokinetic 
processes.  
 Pharmacokinetic processes 
Absorption 
Absorption is defined as the net transfer of drug from the site of absorption into 
the circulating fluids of the body1.  
Oral absorption takes place via gastrointestinal membrane and hepatoportal 
system into the systemic circulation. Drug may get metabolized before it reaches 
systemic circulation and this effect is known as first-pass effect or pre-systemic 
metabolism. 
Bioavailability is a measure of the rate and extent of absorption. Cmax, tmax and 
Area Under the Curve (AUC) are the primary measurements used to determine 
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bioavailability from oral concentration-time curves. Mathematically, it can be represented 
as a ratio of oral AUC and intravenous AUC which is known as absolute bioavailability 
and calculation of the ratio for AUC generic and AUC reference products is referred to as 
relative bioavailability. 
Two products are said to be Bioequivalent if there is no statistical difference exist 
among Cmax, tmax and AUC for the generic and reference products. Relative 
bioavailability is used in determining bioequivalence.  
Distribution 
Distribution is defined as the net transfer of drug from the circulating fluids of the 
body to various tissues and organs. The volume of distribution is a measure of 
physiological volume in which the drug is contained1.  
CVamount d ×=  
Vd is referred to as proportionality constant between amount and concentration. 
Binding properties, whether drug undergoes saturable distribution, if it undergoes 
saturable distribution, under what dose range does it occur, what are the covariates 
affecting the distribution characteristics might be few interesting questions which might 
help in understanding the distribution portion of the disposition of the drug.  
Elimination (Metabolism+Excretion) 
Clearance is defined as the milliliters of blood cleared of drug per minute1.  
tmid
u
R C
t
X
Cl ∆
∆
=  
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t
X u
∆
∆  is the change concentration of drug in urine over a specified time interval. 
Ctmid is the concentration of drug in plasma over the same specified time interval. 
MR ClClCl +=  
ClR and ClM represent renal and all non-saturated metabolism in the body. 
What covariates explain the inter-individual variability? Does the drug undergo saturable 
elimination? How concomitant administration of drugs does affects the clearance?  
Metabolism 
Metabolism is the bioconversion of drug to another chemical form or metabolite, 
mostly by endogeneous enzyme systems involving phase I reactions, such as oxidation 
(often by cytochrome P-450 system), reduction, hydrolysis or dealkylation or by phase II 
reactions such as acetylation, sulfation or glucurodination1. 
Possible questions in this section are What are the main metabolites of the drug 
and what is the enzyme involved in the metabolism, is inter-individual variability present 
and to what extent it affects the metabolism characteristics. 
Excretion 
Excretion is the removal of drug from the body primarily via urine and 
occasionally via faeces, bile, sweat, or exhaled air1. 
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Figure 1. Classification of Pharmacokinetics 
 
   
Pharmacokinetic models 
 
Empirical based models though simple but are outdated and doesn’t give 
resourceful pharmacokinetic information. On the other hand, physiologically based 
pharmacokinetic models are complex, difficult to comprehend but highly useful in 
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understanding the pharmacokinetic processes at tissue level. All the articles discussed in 
this study are related to compartmental models. These models are discussed based upon 
whether the pharmacokinetics undergoes one, two or three compartment model or based 
on a particular mechanism with the distribution and elimination characteristics of the 
central compartment. Drugs in circulating fluids and rapidly perfused tissues are assigned 
to the central compartment, whereas drugs in fluids of distribution and poorly perfused 
tissues are assigned to peripheral compartment. Occasionally, the kinetics of the drug 
may follow a three-compartment model for which the two peripheral compartments 
represent shallow and deep compartments connected to the central compartment. The 
process in which the drug is transferred from one compartment to another compartment is 
determined by first order or zero order rate constants. 
In addition to blood flow and blood volume, partitioning and binding are also 
determinants of drug disposition. Partitioning, a rapid phenomenon, is responsible for 
drug reaching a rapid equilibrium with all tissues in a compartment. The concentration at 
equilibrium is in part due to hydrophilic/lipophillic properties of the structure of the drug. 
Drugs are also capable of binding to plasma proteins, which can reduce or slow 
distribution to tissues. Partitioning, tissue and plasma protein binding depend not only on 
tissues but also on drug properties1.  
2.2. Pharmacokinetic Models 
Approaches to modeling pharmacokinetic data 
There are three basic approaches in modeling pharmacokinetic data: traditional 
compartmental models or classical models, non-compartmental models, and 
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physiologically based models. Models with common features can be linear or non-linear, 
time-variant or time-invariant, deterministic or stochastic. 
Objectives for analysis of pharmacokinetic data: 
1) To summarize the kinetics of the drug  
2) To quantify the kinetic processes of the drug 
3) To explain the pharmacokinetics and to make reasonable pharmacokinetic 
predictions 
Models with common features 
Linear model 
A model is said to be linear if the parameter values are independent of drug dose 
or input function. 
Non-linear model 
Non-linear models are dependent on drug dose or input function. These models 
violate the principle of superposition.  
Nonlinear kinetics can be described with respect to capacity, time, flow and binding and 
how these variables may have an impact on clearance. 
The major distinguishing features between capacity (dose) and time dependency, is that 
the latter involves an actual physiological or biochemical change in the organ(s) of the 
body associated with the drug disposition parameter in question2. 
For example, in time dependence of the auto- or heteroinduction type, the increase in 
drug intrinsic clearance results from an increase in amount of enzyme (e.g. in protein 
synthesis). However, in atypical Michaelis-Menten capacity (dose) dependency, drug 
clearance changes with concentration and such a system should not be considered time-
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dependent simply because the values of pharmacokinetic parameters change with time. If 
that was a true time-dependent system, drug clearance should change with time while 
drug concentration is time invariant. It is still possible that capacity and time dependency 
exist simultaneously2. 
If nonlinearities are observed in the half-life after intravenous administration, this is 
caused by changes in the disposition of drug (Cl, Vc, Cld, Vt). If AUC is changed, this 
may be due to either changes in F or Cl. If the principle of superposition is violated, we 
have either a change in Cl, F or the distribution (Vc, Vt or Cld)2. 
Time-variant Vs Time-invariant 
If the drug concentration-time profile following a given input is independent of 
the time when the input is applied, the system is said to be time-invariant. On the other 
hand, if the model parameters change with time the response will vary with the time of 
application of the input and the system is said to be time-variant. 
Traditional Compartmental Models 
Compartments are chosen to represent the body based partially on an empirical or 
a physiological basis. The number of compartments is determined from best model, 
which fits the data. The route of administration also determines the structure. The model 
must specify transfer between compartments, including the direction of transfer and the 
order of transfer (first order, zero order. etc.). If every compartment is connected to a 
central compartment, then it is referred to as a mammalian model.  
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Assumptions 
Assumptions, and their justifications, for classical pharmacokinetic modeling includes 
existence of barriers between compartments, transfer of drug with certain order and 
certain direction from one compartment to another1.   
Compartment characteristics 
Each compartment consists of group of tissues and drug is homogeneously and 
instantaneously distributed1. 
Drug 
 Elimination of the drug happens only from the central compartment. There is no 
irreversible tissue binding1. 
One compartmental model 
The simplest compartmental model is the one-compartment model with 
intravenous bolus administration and first-order elimination of the drug. This model 
includes an apparent volume of distribution, V. This volume parameter is used to relate 
the amount of drug in the body with the concentration measured in plasma, serum, or 
blood. Volume of distribution is not a physical volume and may be many times larger 
than the size of the subject in cases where the drug is extensively distributed outside the 
blood.  
C
XV =   
X=Amount of drug in the body 
C=Concentration of drug 
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 Figure 2. A one-compartment model with first-order elimination after an IV bolus 1
When elimination follows first-order kinetics, this model can be represented by 
the differential equation, Equation is as follows 
CK
dt
dC
el ×−=  with the initial condition 
V
DC =0  
Rate of change of concentration can be integrated to give equation as follows: 
)exp( tK
V
DC el ×−×=   
  This approach can be expanded to include other routes of administration such as 
IV infusion and extravascular administrations such as oral, intra-muscular, subcutaneous, 
or topical.  
Differential and Integrated equation of extravascular (Oral, GI) administration model is 
given by:                                                                                  
Differential Equation 
CK
V
XK
dt
dC
el
ga ×−×=   
 
Integrated Equation 
 
)]exp()[exp(
)(
tKtK
KKV
KDFC ael
ela
a ×−−×−×−×
××=  
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Multi-compartment models 
Distribution and elimination are occurring throughout the concentration vs. time 
profile. It is the slower distribution with these drugs that requires the use of multiple-
compartment models. In this case, a second compartment can be included in the scheme 
where X1 and X2 represent compartments 1 and 2, 
 
Figure 3. A two-compartment model1
V represents the volume of compartment 1 with k12 and k21 representing the first-order 
rate constants entering and leaving the respective compartments and kel representing 
elimination out of the body. 
This model can be described mathematically with the differential equation. 
221112)( XkXkk
dt
dCV
el ×+×+−=×  
 
Rate of change of concentration can be integrated to give equation as follows: 
 
 
)(exp)(exp tBtAC ×−×+×−×= βα  
 
where 
)(
)( 21
βα
α
−×
−×=
V
kDA  and 
)(
)( 21
βα
β
−×
−×=
V
kDB   
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Non-linear compartmental models 
As discussed in previous sections, we include nonlinear processes if there exists 
saturable metabolism or protein binding. For example, for some drugs one or more 
metabolism processes may follow Michaelis-Menten kinetics. 
Elimination k described in equation 
CK
CV
dt
dC
m
m
+
×−=  with a nonlinear metabolism process 
with the parameters Vm (maximum velocity) and Km (Michaelis constant)1. 
At high concentrations the denominator K + C approaches C and the above Equation 
becomes zero order with mV
dt
dC −= 1.  
Non-compartmental models 
This process can also be named as non-parametric pharmacokinetics because a 
structure with compartments and corresponding parameters are not modeled, but instead 
the response is modeled. The drug is distributed through stochastic random I processes: 
convection and diffusion (through various membranes and tissues) 1 
There are two main assumptions inherent to this approach. 
Superposition 
This assumption relates the response and the inputs where simultaneous inputs 
should produce the response equal to when the inputs are given separately produces the 
sum of independent responses. 
For example, if an IV dose and an oral dose were given and the response to each was 
known, then when both are given simultaneously, the response would be the sum of the 
two separate responses. This is the principle that is used to determine the response 
following multiple doses1. 
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Time invariance 
This assumption is that if a certain dose is given produces the same and a certain 
response regardless of the dose given at any time. However, some drugs exhibit time-
dependent pharmacokinetics. Examples of these situations can be when a dose given in 
the morning may not produce the same result as when it is given at night and the 
elimination rate changes with saturable elimination.  
Physiologically Based Pharmacokinetic models (PBPK) 
PB/PK models should be viewed as a powerful means to represent drug 
disposition based on mass transport principles, and should he considered as a modeling 
approach when the emphasis is on understanding the pharmacokinetic properties of the 
drug in tissues. Physiological models are developed a priori in that independent 
experimental data are used to propose a model before the experimental response is 
available. But empirical and compartmental models are formulated after measurement of 
the experimental response. 
Many of the same assumptions for the compartments of the traditional models 
apply here as well. In addition, blood flow must be known or estimated through each 
compartment.  
Hepatic clearance models are further divided into the well-stirred and parallel 
tube models and they have been used to describe hepatic elimination of drugs. The 
amount of drug entering and leaving the compartment should be determined. 
Assumptions 
Each organ system forms a separate compartment and the drug is homogeneously 
and instantaneously distributed within that compartment  
 15
Partition coefficient can be determined from the concentration of the drug in the tissue 
compared to the concentration in the blood, 
Rate constant is determined by the barriers between compartments in 
physiological systems. This transfer rate is dependent on the blood flow within an organ. 
Each compartment has a characteristic clearance rate and is constrained by the rate of 
blood flow1. 
Drug 
Elimination is only from certain compartments that are specified in the model, for 
example the liver and kidneys with no irreversible binding of the drug to the tissue1. 
Features of PBPK models 
• Mass balance approach to characterize drug disposition 
• Differential equations are utilized to describe model systems 
• Helps in understanding drug disposition in tissues 
• Predicts drug concentrations under different physiological and pharmacological 
conditions 
• Can be scaled from animals to humans1
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Table 1. Comparison of modeling techniques 
 
Comparison Empirical or  
Non-compartmental 
Modeling 
Compartmental  
Model 
Physiologically based 
pharmacokinetic model 
Complexity in 
mathematical 
modeling 
Simple Intermediate Complex and difficult to 
determine many of the 
physiological or 
anatomical parameters 
Structural 
relevance 
(Physiological or 
anatomical 
relevance) 
Attempts to model 
the response rather 
than the structure of 
the process, hence 
little explanation 
why the drug 
exhibits a certain 
kinetic profile 
Difficult to assign 
structure to the 
model and the 
resulting 
parameters, does 
little to address the 
specific structure of 
the kinetic process 
Compartments as well as 
the model parameters that 
are determined, such as 
blood flow, elimination 
rate, and partitioning 
coefficients 
Assumptions Drug distribution 
generally occurs by 
two stochastic 
processes: 
Convection and 
Diffusion. Two 
assumptions that 
must be verified for 
this approach are 
superposition and 
time invariance. 
Many of the 
assumptions are 
difficult to verify 
Many parameters and 
assumptions cannot be 
verified 
Data collection Blood and urine 
samples 
Blood and urine 
samples 
Blood, urine, tissue 
concentrations and organ 
blood flow rates 
Study objective  To summarize 
kinetics, quantify a 
pharmacokinetic 
process, or make 
pharmacokinetic 
predictions 
To develop 
descriptive 
pharmacokinetics  
of a drug 
Drug discovery process to 
identify the kinetics and 
action of a new compound 
Disadvantage Does not help in 
understanding the 
overall mechanism 
of the kinetics of 
the compound 
studied 
Not meaningful to 
summarize in terms 
of structure specific 
parameters that do 
not have 
physiological or 
anatomical 
significance. 
Complex and many 
parameters and 
assumptions cannot be 
verified. Massive sample 
collection is required and 
many validation 
experiments need to be 
done 
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PK/PD MODELS 
PK/PD model relates the time course of pharmacological effects with plasma drug 
concentrations to predict the temporal pattern of their pharmacological effects. 
Frequently used PK/PD models  
Linear PK/PD model 
 The linear model assumes drug concentration is proportional to the observed drug 
effect, as shown in the following equation: 
CbEE ×+= 0  
Where E0 is the baseline effect and b is a slope. 
Sigmoid Emax PK/PD model 
 Effect (E) relates to the concentration(C) as follows, 
γγ
γ
CEC
CEE +
×=
50
max  
This relationship can be theoretically described based on the interaction between γ drug 
molecules and one common interaction site. However, in most cases γ only serves as a 
shaping factor to allow for a better data fit. Therefore, γ is not necessarily an integer 
value. The steepness of the concentration-effect curve depends on the magnitude of γ; the 
larger γ, the steeper the linear phase of the log-concentration-effect curve. The Emax 
model can be considered as a special case of the sigmoid Emax model with γ=11.  
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2.3. Population Pharmacokinetics 
Introduction 
This section comprises of an overview of the purpose of population 
pharmacokinetics and its significance in the drug development process. We also describe 
different types of population approaches and their shortcomings, many of which are 
overcome by nonlinear mixed effects modeling. In order to understand the model 
building process with this approach, the mathematical concepts, algorithms, statistical 
models, assumptions and issues involved behind this approach is discussed in detail. 
Finally, we walk through the steps involved in the process of model building. 
Why do we go for population pharmacokinetics? 
High interindividual variability in pharmacokinetic parameters for all major 
anticancer drugs: three to tenfold interindividual variation in systemic exposure have 
been reported, even in patients without renal or liver failure or other metabolic 
dysfunction. A fundamental goal is to provide quantitative platform to assess if and in 
what manner a patient’s covariates impact on the drug’s pharmacokinetics. 
When the pharmacokinetic model is constructed for an individual, we understand 
the pharmacokinetics for that particular individual which is traditional pharmacokinetics. 
But in the phase of drug development, participants who vary in covariates such as 
demographic, pathophysiological or environmental are quantified as fixed effects and 
also vary at random quantified as random effects (unexplained part of the variability). 
Both types of effects affect the pharmacokinetics of a drug. Hence we construct a mixed-
effects model to quantify the fixed effects and random effects of pharmacokinetic 
parameters, which is the hallmark of population pharmacokinetics. 
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The key pharmacokinetic parameters, including volume of distribution and 
clearance, vary from individual to individual which are re-parameterized in terms of 
covariates in understanding the inter-individual variability for dose individualization. 
Dose individualization produces beneficial effect when drugs have narrow therapeutic 
index and toxicity effects. 
Thus population pharmacokinetics recognizes variability as an important feature 
that should be identified and measured during drug development or evaluation. Also, it 
seeks to obtain relevant pharmacokinetic information in patients who are representative 
of the target population to be treated with the drug. 
What is the significance of the estimates of identified variability and unexplained 
variability? 
Background: The primary objective of dose administration is to achieve drug 
levels within the target range of clinical effect. Drug levels outside the target range are 
attributable to the uncompensated variability in the relationship of dosage to steady state 
drug concentration. 
Discussion: The magnitude of the unexplained (random) variability is important 
because the efficacy and safety of a drug may decrease as unexplainable variability 
increases. Thereby unnecessary failure rates of trials might be avoided. 
Concentrations appear to vary due to inexplicable day-to-day or week-to-week 
kinetic variability and due to errors in concentration measurement. Estimates of this kind 
of variability (residual intrasubject, interoccasion variability) are important for 
therapeutic drug monitoring using the empiric Bayes approach. 
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The knowledge of the relationship between concentrations, response, and physiology is 
essential to design dosing strategies for rational therapeutics that may not necessarily 
require therapeutic drug monitoring. 
When do we perform population approach? 
When the population under the investigated trial is heterogeneous, the application 
of population approach is more appropriate. In drug development, the population 
approach can help increase knowledge of the quantitative relationships between drug 
input patterns, patient characteristics, drug disposition, and responses. The population 
approach may increase the efficiency and specificity of drug development by suggesting 
more informative designs and analyses of experiments. The population approach can also 
be applied to phases 2 and 3 of drug development to gain information on drug safety 
(efficacy) and to gather additional information on drug pharmacokinetics (and 
pharmacodynamics) in special populations, such as the elderly. It is used to characterize 
drug disposition in large populations. It is also useful in postmarketing surveillance 
(phase 4) studies. 
Utility of population-based pharmacokinetic model 
• The clinical significance of a population pharmacokinetic model is that it may be 
used to prospectively individualize drug therapy to achieve a target systemic 
exposure. In simple terms, it aids in specific dosing guidelines sought for 
subpopulations and individuals. 
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• It helps in the development of limited sampling strategies utilized in phase II 
clinical studies, considerably reducing patient discomfort and labor intensity and 
therefore makes PK studies easier to perform and on pharmacokinetic-
pharmacodynamic relationships. 
Population analysis methods 
Pooling sparse data from several individuals can provide valuable information 
about drug disposition in the population. 
1. Naïve Pooled Data (NPD) 
This method combines all the data as if they come from a single individual. Residual 
variability is overestimated and cannot estimate parameters for an individual. 
2. Naïve Averaged Data (NAD) 
This method obtains the average concentration across individuals at each time point. 
Disadvantages of this method are: not ideal for investigation of sources of variability, 
biased estimates of the true “mean” parameters across individuals, need experiments with 
identical sampling times across subjects. 
3. Standard Two Stage (STS) 
Step 1: Estimate an individual subjects PK and/or PD parameters from rich data 
using standard fitting procedures. 
Step 2: Estimate the population parameters across the subjects. 
Using regression analysis techniques, a covariate relationship between PK 
parameters across and/or within subjects and fixed effects can be investigated. 
Bias: Mixed-effect modeling vs. STS 
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Parameters for the individuals are estimated and mean values of the parameter 
have little or no bias. Covariates can be included in the model. But variance-covariance 
of parameters across subjects is biased. Numerous blood samples at appropriate times are 
required to obtain accurate estimates. STS performs well when residual variability is 
absent and provide upwardly biased estimates of inter-individual error as residual error 
increases. 
Mixed effect modeling results in less biased estimates when residual error is 
present and sparse blood sampling strategy at appropriate times is enough to obtain 
accurate estimates3. 
 
Development of population model described with an example 
Assumptions about Random Error 
Ordinary Least Squares OLS 
Assumes a homoscedastic error structure (common or homogeneous variance 
regardless of response). The random error is the same for all observations. 
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Weighted least squares WLS 
Assumes a heteroscedastic error Structure (variance changes with the response). 
The random error is assumed to he some function of the observed data (i.e. if wi = 1 / Y 
the variance is proportional to the response). 
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Extended least squares ELS 
Assumes heteroscedastic error structure. The variance is expressed as a model 
parameter along with the structural model parameters. ELS is designated as a maximum 
likelihood (as opposed to least squares) if the random effects are assumed to be normally 
distributed. 
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The intra-individual model is 
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i
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where yij the jth observation for the ith individual 
           xij all independent variables used to predict the jth observation for the ith 
individual 
           Pi are the structural model parameters for ith individual 
           f (xij, Pi) the model prediction for yij 
           εij random error associated with yij 
Different types of residual random effects model 
Residual random effects are the combination of intra-individual error and residual 
error. Residual errors (ε) are assumed to be identically, independently distributed~ N (0, 
σ2). 
The residual random error model can be: 
1. Homoscedastic (additive, or constant variance) 
1ε+= FY  
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2. Heteroscedastic (proportional or constant coefficient of variation (CV)) 
)1( 1ε+×= FY  
3. Exponential (approximates constant CV) 
)exp( 1ε×= FY  
4. Combination additive and proportional error 
21 )1( εε ++×= FY  
The inter-individual model 
Vii vV ηθθ +×+= 121  
),,( iii vgP ηθ=  
where vi the independent variables needed to predict Pi
           θ the population mean parameters 
           ηi the random inter-individual errors for the parameters of the ith individual 
           ),,( iivg ηθ  the model describing Pi 
Different types of inter-individual random effects model 
Usually assumed to be identically, independently distributed ~ N (0, ω2) 
1. Homoscedastic (additive, or constant variance) 
ViiV ηθθ +×+= 121 cov  
2. Heteroscedastic (proportional or constant coefficient of variation (CV)) 
)1)(cov( 121 ViiV ηθθ +×+=  
3. Exponential (approximates constant CV) 
)exp()cov( 121 ViiV ηθθ ××+=  
The Population model is as follows: 
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Methods involved in the inter-individual variability parameter estimation are first 
order approximation, first order conditional estimation, expectation maximization 
algorithm, discrete/continuous nonparametric maximum likelihood and Bayesian 
inference using Gibbs Sampling: Bayesian methods implementing Markov chain Monte 
Carlo methods. 
Pharmacokinetic parameters for individuals 
Bayesian estimation 
The prior distribution of the parameters across a population of subjects and the 
actual data from an individual are used when estimating the parameters for an individual. 
The estimation of parameters in the individual uses the posterior probability of the 
parameters. 
( ) ( ) ( ) ( ) ( )popiTpopiprediobsiiTprediobsii yyyyOBJ φφφφφ −Ω−+−−= −−∑ 11  
When the number of samples for an individual is small the prior distribution of 
the parameters usually predominates. When the number of samples for an individual is 
large, the data from the individual is more important than the prior distribution of the 
parameters. 
Advantage of this estimation is sparse sampling and disadvantages of this 
estimation needs estimates of the priors for the parameters and residual error variance and 
fit may be dependent on priors3. 
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Conditional estimation procedures 
POSTHOC using FO and FOCE, Laplacian conditional estimation, Hybrid 
estimation are some of the estimation methods to estimate ηs for each individual. 
Model Development process 
Step 1: Define the modeling objectives  
The first step in the development of mathematical model is to define the modeling 
objectives. A good understanding of the modeling objectives is useful when making 
critical decisions during the modeling process. 
Step 2: Exploratory analysis 
Population PK analysis involve large amounts of response data (PK or PD) and 
covariate, demographic data. Distribution analysis of covariates under investigation, 
covariate correlation analysis, and investigation into disease process time course if 
necessary. An examination of the dataset can reveal errors or provide hints about 
unexpected relationships in the data. 
Step 3: Define a preliminary structural model 
The structural model is the PK model that describes the fate or the effect of the 
drug. A common assumption is that the model is the same for all individuals within the 
population.  
Step 4: Define preliminary random effect models 
NONMEM estimates population parameters as typical parameter values with 
corresponding interindividual variability. This is accomplished by allowing each 
individual’s data to be described by subject-specific pharmacokinetic parameters Pi. This 
parameter is assumed to come from the distribution of parameters in the population 
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)exp( ipopi PP η×=  where η~N (0, ω2) 
For mixed effects models, the residual error corresponds to the difference between 
the observed concentration and the predicted concentration by individual parameters (Pi). 
Step 5: Obtain initial estimates of parameters 
The ability of non-linear regression model to converge successfully at a global 
minimum is sometimes dependent upon the initial estimates that one uses to fit the model 
to the data. With most nonlinear least-squares analysis, local minima exist such that a 
number of initial estimates must be used to ensure that a global minimum is obtained. 
Step 6: Estimate the population parameters for the basic structural model 
This step is accomplished by assessing the goodness of fit of the model to the 
data, which is evaluated by the statistical significance of minimizing the objective 
function value (OFV). 
OFV provided by NONMEM used for comparison of models, discrimination 
between hierarchical models based on OFV using the log-likelihood ratio test.  
Step7: Estimate individual parameters 
Individual Bayesian estimates of the pharmacokinetic parameters are obtained by 
using the POSTHOC option in NONMEM; for each subject, individual pharmacokinetic 
parameters are calculated taking both the individual observations and population effects 
into account. 
Step8: Explore relationships between covariates and structural model parameters 
The relationships between the individual pharmacokinetic parameter estimates 
and the covariates is visually inspected and investigated using stepwise procedure. 
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A generalized additive modeling procedure (GAM) is applied to select explanatory 
variables and calculations using Xpose. 
Step9: Build covariate model 
Covariates that correlated significantly with the pharmacokinetic parameters, as 
indicated by Akaike Information Criterion (AIC) is selected for testing in NONMEM. 
Step10: Perform model checking 
Model checking is done by checking assumptions and models fit and determine 
predictive performance of the population pharmacokinetic model by internal validation: 
data splitting cross validation or resampling and external validation. 
Advantages 
The population model built using NONMEM can estimate inter-individual 
variability of the parameters, random residual error and parameters for individuals. 
Additional advantages are covariates can be included in the model, can be used with 
dense data or sparse data and correctly handles differing numbers of data points per 
patient (imbalance). Population approach also allows us to analyze data from different 
studies differing in dose and frequency. 
 
3. DESIGN 
3.1. Collection of pharmacokinetic articles 
Literature selection 
Literatures were selected to gather information on pharmacokinetic articles for 
different anti-cancer drugs. Since articles are related to drugs, EMBASE database was 
also chosen in addition to MEDLINE and ISI database. EMBASE has only 37% overlap 
with MEDLINE and is particularly strong in the area of drugs. We follow general search 
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strategy and apply search criteria for relevant article collection. We delete articles based 
on deletion criteria. 
3.1.1. Introduction about search database 
MEDLINE 
The MEDLINE database is produced by the National Library of Medicine (NLM) 
and covers the fields of medicine, dentistry, psychiatry, public health, pharmacy, nursing 
and other biomedical sciences 
EMBASE 
The EMBASE database is produced by Elsevier Sciences and covers more than 
3,500 international journals. The main focus indexes biomedical literature with emphasis 
on drugs & pharmacology. This database is strong on European and Japanese titles. 
EMBASE offers drug literature record access through chemical name, drug trade name or 
manufacturer nameprecise and reliable indexing using EMTREE, a hierarchically-
ordered, synonym-controlled thesaurus — with almost 42,000 drug and medical indexing 
terms and 180,000 synonyms. 
ISI 
ISI covers over 8,000 international journals in the sciences, social sciences, and the 
arts and humanities. 
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3.1.2. Search criteria and search strategy 
 
Developing the search strategy is the process of: 
• Formulating the search query  
Define the question relevant to what we are looking for and identify the main terms or ideas 
to combine the ideas with AND or OR from the search topic.  
• Choosing the appropriate database  
• Selecting the best Medical Subject Headings (MeSH) or terms to describe your topic  
• Combining the terms or sets 
• Limiting your retrieval to appropriate references or citations  
      After performing a search, a list of articles should appear which contain the main terms from 
the search strategy.  
If the articles are too broad or general, then  
• Add more search terms or more specific terms using combine and limit 
• Search terms with common keywords used in the title of articles 
• Consider related or similar terms for better results  
• Focus/explode to restrict/expand main subject headings options.  
There are two major steps involved in article search:  
• Combine: “Combine” sets using the Boolean AND or OR  
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 • Limit: “Limit” restricts the search to logical variables such as English language, human 
subjects, age groups, gender, publication types, publication years, etc.  
Validation and reliability: Validation is achieved by using comparable search criteria and 
search strategies across different databases (e.g. Medline and Embase) and reliability by utilizing 
different user interfaces (PubMed and Ovid for Medline) is achieved. 
Useful functions in article search 
Explode: “Explode” is an option you will make about each subject heading (MeSH) 
during the search process. Exploding will retrieve MeSH terms that are part of the family or tree 
of the original term5.  
Focus: “Focus” will retrieve only those articles where the term is emphasized, a major 
point, or a main topic5.  
Deletion of articles: 
Articles were deleted if their main focus was irrelevant to the purpose. Thus articles with 
main focus was CT imaging, physics, computer model, mathematical model (out of scope), 
molecular model, chemical and physical properties of drug, focus on renal functions, immuno-
compromised and immunosuppressant drugs, toxicity analysis, pharmacogenomics, dynamics 
including receptor action, ligands, biologic and molecular mechanism, monoclonal antibodies or 
animal models were deleted. 
1) Medline via PubMed 
a) The search for PK articles in PubMed was done through an Endnote connection file. 
Keyword “pharmacokinetics” was entered in the title field to obtain set of articles. Keywords 
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 “cancer and model” are entered in a new search field to obtain another set of articles. These sets 
are combined using AND operator. This resulted in 254 articles. Deleting the articles before 
1995 reduced the total to 150 articles. Furthermore, articles considered irrelevant to the 
collection were deleted using pre-defined deletion criteria finally resulted in 104 Pk articles. 
b) By using different search criteria with keywords “population”, “pharmacokinetics” and 
particular type of anti-cancer drug limited to Title/Abstract, publication type by clinical trial, all 
ages, publication date from year 1995-2003, English language, Human with no subsets and 
gender yielded 10-20 articles on each drug6 using PubMed. Relevant articles were chosen which 
resulted in 93 articles. 
Certain drugs (Triptolein, Propecia, Imuran, Femara etc.) didn’t produce any results with 
the above search criteria. This may be attributable to the usage of brand names or lack of 
population models for these drugs or both. 
c) Another way of searching in PubMed by exploding “Antineoplastic agents” by 
Medical Subject Heading (MeSH) resulted in 9 subheadings and the search resulted in 497920 
articles. The keyword pharmacokinetics model* was used in the search field resulting in 1817 
articles. Combining the searches (497920 and 1817 articles) gave 88 articles.  
2) ISI via Web of Science 
Keywords “pharmacokinetics”, “model” and “anti-neoplastic agents” were used in 
separate search fields resulted in 373 articles. 
3) Medline via Ovid 
Step1: The use of the keywords “pharmacokinetics model$” in the search field limited to 
humans and English language resulted in 688 articles.  
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 Step 2: By exploding antineoplastic agents using MeSH produced 200837 articles. 
Combining steps 1 and 2 resulted in 100 articles. 
4) Embase via Embase.com 
Step1: Drug search is used in exploding anti-neoplastic agent published years from 1996-
2004 restricted to human and English (128842 articles)  
Step2:  Advanced search is used for the keyword “pharmacokinetics” (37222 search 
results)  
Step3: Again, advanced search is used for emtree keyword (similar to MeSH) model, 
which constituted non-biological and theoretical model (22602)  
Step 4: Combining 1, 2 and 3 resulted 136 articles. 
An additional search was done using these criterion “pharmacokinetic model” and “population” 
as keywords in the advanced search for population pharmacokinetic articles. Irrelevant articles 
were discarded from the 300 articles according to the deletion criteria. 
Table 2. Number of articles in each Medline provider collected on anti-cancer drugs 
Drugs Ovid 
 
ISI Pubmed Embase
 
Overlap* Total (by
Drug) 
Carboplatin 4(4) 9(8) 16(8) 7(6) 8 28 
Cisplatin 2(2) 15(10) 9(5) 7(6) 7 26 
Topotecan 3(3) 4(5) 7(4) 5(3) 8 11 
Irinotecan 2(1) 4(3) 8(4) 5(5) 5 14 
Etoposide 4(4) 12(6) 8(6) 8(6) 6 26 
Paclitaxel 6(6) 32(14) 21(12) 4(3) 14 29 
5-Fluorouracil 6(4) 25(14) 19(10) 7(5) 18 23 
Total  27 101 88 43  259(157)
 37
 *Represents duplicates over all of the databases. 
The numbers in brackets represent the number of journals from which the articles were 
collected.  
Discussion on results 
            Results from the sampled articles had 17 articles in common using different user 
interfaces (PubMed and Ovid) accessing Medline out of 100 articles. This may be attributable to 
the difference in indexing of keywords, MeSH and comparable search criteria. The major reason 
we might get different results from PubMed and Ovid are the ways in which the two databases 
process the search query. For example, PubMed automatically explodes MeSH terms to pick up 
narrower terms, while Ovid requires you to make that choice. The way each system maps your 
original search term to the official MeSH terms is different as well and could lead to different 
results. For e.g., when we use Medical Subject Heading “neoplasms”, the subheadings under this 
topic differs in PubMed and Ovid. Also, when we search using Ovid and PubMed, the collection 
of articles in Ovid is 4-6 times less compared to PubMed. The reason is PubMed also retrieves 
the articles using the keyword search. For e.g., when we combine keywords “pharmacokinetics”, 
“cancer” and “model” in both PubMed and Ovid, we get 3541 articles in pubMed compared to 
746 articles in Ovid. This could also possibly lead to different search results. It is more likely we 
would collect the article, if one of the keywords used in the search criteria were indexed in the 
article. For e.g., this article “A sequential Bayesian algorithm for dose individualisation of 
carboplatin” is retrieved from ISI, EMBASE, and PubMed but not from Ovid. Another example 
“Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer” found 
in ISI and PubMed but not retrieved in Ovid for the same reason. On the other hand, 
“Mechanism-based pharmacokinetic model for paclitaxel” and “Population pharmacokinetic 
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 modelling of unbound and total plasma concentrations of paclitaxel in cancer patients” are found 
in both PubMed and Ovid because Ovid was able to pick one of the MeSH terms used in 
keyword search. Results accessed from MEDLINE and EMBASE were entirely different sets 
and it can be understood from the fact that EMBASE focuses on drugs and worldwide journals, 
especially European and Japanese journals. For e.g., This article “Population pharmacokinetic 
analysis of cisplatin and its metabolites in cancer patients: Possible misinterpretation of 
covariates for pharmacokinetic parameters calculated from the concentrations of unchanged 
cisplatin, ultrafiltered platinum and total platinum” is from the journal “Japanese Journal of 
Clinical Oncology”. EMBASE.com would retrieve different results in part because there are 
many journals from EMBASE in that database that are not included in MEDLINE. This article 
“Long-term body retention and tissue distribution of platinum in cisplatin treated cancer 
patients” is from the journal “Journal of Radioanalytical and Nuclear Chemistry” which is not 
found in MEDLINE. Another e.g. was the article “Differences in metabolism of 5-fluorouracil 
and 5-fluorouridine and regulation by glucosamine in human colon cancer multicell tumor 
spheroids” from the journal “NMR in Biomedicine” which is also not found in MEDLINE.Any 
other difference would be attributed to the way in which the database processes queries. Though 
EMBASE main focus indexes biomedical literature with emphasis on drugs & pharmacology, 
ISI resulted in the largest set of articles (373) as compared to 134 articles from EMBASE. The 
possible reason is ISI includes over 8000 journals from all different disciplines while MEDLINE 
includes over 4000 journals from health sciences and related literatures. Also, we get more with 
ISI because we are doing a simple keyword search (collect articles that mention the search terms) 
rather than using a subject heading approach. Thus, different search results are attributable to one 
or combination of the following reasons. How the database handles the MeSH for the keyword 
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 search and what are the sub-headings included in the MeSH, inclusion of variety and type of 
journals and comparable search criteria. 
          A class of drugs is selected from the results namely Paclitaxel falls under Taxol, 5-
Fluorouracil (5-FU) under Fluoropyrimidine, Carboplatin and Cisplatin under Platinum and 
Topotecan, Irinotecan and Etoposide under Topoisomerase inhibitors. ISI had correspondingly 
three times the collection of articles in total compared to other databases. 
3.2. Questionnaire 
The following questionnaire is used for collecting basic information from the 
pharmacokinetic articles. Other useful or peculiar information is added from the article without 
the help of questionnaire. 
1) What are the drugs and its metabolites involved in the study? 
2) What are the drug indications? 
3) What are the dose ranges, levels and types of administration? 
4) Is the drug sequence dependent when concomitant drugs are used? 
5) Is there a drug interaction between the administered drug and the concomitant drugs? If so, 
then we have the possible sub-questions: 
a) How does the administered drug affect the dose-response relationship?  
b) Is there a significant influence of the administered drug on the concomitant drug   
disposition? 
c) How does drug interaction affect area under the curve and does it affect the disposition 
parameters?  
6) Does the drug undergo linear or non-linear pharmacokinetics? Supposing the parameters show 
non-linear characteristics, what are the reasons attributed to this scenario?    
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 7) How is the pharmacokinetic model described and what are the possible models used to 
describe the concentration-time data? Is the drug schedule dependent or dose dependent? 
a) Absorption 
Is the drug given orally? How is the absorption parameters affected? Does the absorption 
phenomenon have time-lag? What is the oral bioavailability? Does the oral 
administration exhibits wide inter-individual variability? 
b) Distribution 
Does the drug undergo saturable distribution? What is the mechanism involved in the 
properties of distribution? Does the distribution properties differ for subpopulation? What 
are the covariates explaining the variability in the volume of distribution? Does the drug 
binds to different types of proteins in blood cells? Is the drug found as bound and free 
drug? How is the bound drug e.g. any covariates affecting binding properties? 
c) Elimination 
Does the clearance vary in the sub-population? What are the covariates affecting the 
clearance? Does the drug undergo saturable elimination? What are the enzymes involved 
in the metabolism and is there genetic polymorphism? Is the clearance parameter time 
variant or time-invariant? 
Is clearance dose or time or schedule dependent? Are there any rate-limiting enzymes and 
what are the inhibitors used to inhibit metabolism?  
8) PK/PD relationship 
What are the common hematological and non-hematological toxicities? What is the dose-limiting 
toxicity and maximum tolerated dose? What are the possible models, which describe the PK/PD 
relationship? 
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4. RESULTS 
The collected information from the PK articles is compiled in a structured format. These 
results comprises of templates on four classes of drugs. Some articles for each class are excluded 
as the information does not contribute to the template or due to redundant information. 
4.1. Templates on drugs 
4.1.1. PACLITAXEL  
Drug and metabolites involved in the study 
Paclitaxel is the parent drug and 6-alpha-hydroxypaclitaxel, 3’p-hydroxypaclitaxel and 6-
alpha, 3’-p-dihydroxypaclitaxel are its main metabolites21.  
Drug indication 
Paclitaxel is used in the treatment of breast cancer, ovarian cancer, non-small cell lung 
cancer and esophageal cancer and is widely used in the treatment of advanced breast cancer. 
Paclitaxel alone, as well as combination of CP and 5-FU has significant clinical activity against 
upper aerodigestive tract cancers22. 
Dosage and administration 
Drug is administered by Infusion for 3h and the dosing levels are 135mg/m2, 175mg/m2, 
and 235mg/m2 23. Dose ranges from 135 mg/m2 to 250 mg/m2 and is administered by intravenous 
infusions of 1-24h duration24. Paclitaxel can be administered upto 250 mg/m2 with G-CSF 
support 21, 22. The recommended dosage for paclitaxel is 100 mg/m2 when administered along 
with Gemcitabine 1500 mg/m2 as it exhibits linear pharmacokinetics25. Weekly administration of 
paclitaxel has demonstrated efficacy together with a more favorable toxicity profile26. 3-h 
infusion has reduced hematological toxicity compared to 24-h infusion without compromising 
efficacy22. Paclitaxel is administered with the cremophor EL (CrEL) due to its poor solubility6. 
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 Drug sequence 
Paclitaxel is sequence dependent when it is administered with cisplatinum agents, which 
can be shown with increasing toxicity22. Doxorubicin-paclitaxel is better compared to paclitaxel-
doxorubicin sequence as the former resulted in grade 2 and 3 stomatitis27. Cmax and clearance of 
doxorubicin was affected by paclitaxel-doxorubicin sequence27. There was a significant 
difference for the metabolite 6 alphahydroxypaclitaxel (6 OHP) AUC and higher 6 OHP is 
observed when carboplatin is administered before paclitaxel28. 
Drug interaction 
Paclitaxel and CrEL with epirubicin inhibit production of the metabolite epirubicinol but 
marked increase in inhibition is found by CrEL. Paclitaxel-Epirubicin interaction is found in Emax 
model exhibiting 50% reduction in Absolute Neutrophil Count (ANC) at 7.7h compared to 
11.16h with paclitaxel alone29. This difference may be due to the combined effects of Epirubicin 
and Paclitaxel and there is significant influence of paclitaxel/cremophor EL on epirubicinol and 
epirubicin disposition; however, both of these drugs do not interfere with Gemcitabine 
disposition30.  
Pharmacokinetics 
Paclitaxel undergoes non-linear pharmacokinetics6, 23,30,31. Nonlinear pharmacokinetics is 
reflected by a disproportionate increase in area under the curve (AUC) in relation to increased 
dose. This is attributable to saturable distribution and saturable elimination and may be partly 
due to Cremophor EL (CrEL) binding. There is three-fold inter-individual variability in the 
paclitaxel disposition at any dose level. This variability can be accounted by understanding the 
various biological factors that may influence paclitaxel disposition and polymorphism of 
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 paclitaxel metabolism22. Population studies show Body Surface Area (BSA) explained the 
variability in clearance and volume of distribution33. 
Pharmacokinetic model 
The disposition is modeled as two-compartment model22, 25,32,33. In another study, three-
compartment, nonlinear distribution and elimination model is fitted to the plasma concentration-
time data6, 29,31. Two or three-compartment model can be fit to the unbound concentration-time 
profile6.  
Absorption 
Distribution and binding properties 
Paclitaxel is found as bound and unbound drug6, 26,33. Unbound drug displays linear 
pharmacokinetics. Cremophor EL (CrEL) traps this drug, thereby less available for distribution 
to tissues, metabolism and biliary excretion. CrEL concentration affects the binding properties: 
At high CrEL, paclitaxel is mainly bound to CrEL and at low concentrations, it shows linear 
binding to plasma proteins and blood cells. In the absence of CrEL, plasma protein binding 
would be 85% and it has been shown to bind to both albumin and α1-acid glycoprotein.  
Bound plasma concentration is modeled by three compartments with a binding compartment 
directly proportional to CrEL concentrations, a linear binding and a nonlinear binding to other 
plasma components.  
“Mechanistic basis of paclitaxel properties of distribution has been determined with 
micelle trapping with Cremophor EL (CrEL), distribution to RBCs, and binding to 
albumin, alpha acid glycoprotein, and platelets6”.  
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 Elimination (Metabolism + Excretion) 
Clearance of unbound and total paclitaxel is significantly different among the elderly and 
younger age group with negative correlation (clearance is faster in elderly than the younger age 
group) whereas it is reduced with concomitant administration of verapamil26. Clearance is 
unaffected when the drug is administered for 96 h compared to 3-h infusion34. Paclitaxel and 
cremophor EL are good substrates for P-gp and competition for this carrier protein may result in 
decreased hepatic clearance29, 35. 
Metabolism 
Paclitaxel undergoes extensive metabolism and biliary excretion6. The three main 
metabolites are formed via CYP2C8 and CYP3A4 enzyme mediated pathways35. Cytochrome 
P450 (CYP450) enzyme involved in the metabolism of paclitaxel to its major metabolite 6α- 
hydroxyl paclitaxel22. 
6-alpha-hydroxypaclitaxel, 3’p-hydroxypaclitaxel and 6-alpha, 3’-p-dihydroxypaclitaxel 
are the major metabolic products of products found in human bile21. Higher paclitaxel and 6-
alpha-hydroxypaclitaxel AUC levels are found with liver function disturbances resulting in more 
pronounced neuropathy21. There is a difference found in metabolism among patients23.  
Exposure-Toxicity/Effect relationship 
In one of the studies, paclitaxel-cisplatin (paclitaxel followed by cisplatin) combination 
chemotherapy is found to be efficacious and feasible for an ovarian cancer patient under 
hemodialysis; however, Grade IV neutropenia and grade III thrombopenia are observed36. Dose 
Limiting Toxicity (DLT) is febrile neutropenia at the dose of 157.5 mg/m2 and Maximum 
Tolerated Dose (MTD) of paclitaxel is 140 mg/m2/7 days37. Cumulative neuropathy is the major 
DLT only after multiple cycles of paclitaxel followed by cisplatin22. Frequently encountered 
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 side-effects are neutropenia, neuropathy, asthenia and alopecia25, 28,29,36. Older age and 
hyperglycemia are associated with greater neurotoxicity38. 
 
4.1.2. 5-FLUOROURACIL  
 
Drug and metabolites involved in the study 
Oral pro-drugs of 5-FU: 5-fluoro-pyrimidonone (5FP), Capecitabine, Ftorafur 
5-FU metabolites: 5’-deoxy-5 fluorocytidine (5’-DFCR), 5’-deoxy-5-fluorouridine (5’-DFUR), 
dihydrofluorouracil, α-Fluoroβ-Alanine (FBAL) 12,13,40,42
Drug indication 
5-Fluorouracil (5-FU) is widely used in the treatment of colorectal and breast cancer. 5-
FU is also used in the treatment of advanced gastrointestinal cancer, breast cancer, and variety of 
malignancies of epithelial origin, head and neck cancers, 5-FP in anti-tumor activity in P 388 
leukemia models8. Greater hepatic metabolism shows that the drug is efficacious against liver 
metastases or primary liver cancer8. Capecitabine shows clinical effect for patients with taxane-
refractory breast cancer and as first-line monotherapy for patients with metastatic colorectal 
cancer12.  
Dosage and administration 
5-FU dosage is 400 mg/m2 by loading dose and then 600 mg/m2 by continuous infusion7. 
5FP is administered orally once daily for 5 days every 4 weeks. Initial dose level is 23 mg/m2/d 
and dose escalation by 30-35% till dose-limiting toxicity is observed8. In advanced colorectal 
cancer, continuous i.v. Infusion has resulted in a significantly higher response rate and less 
toxicity, compared with i.v. Bolus injections9. The starting dose for renal impairment is reduced 
to 75% of the standard starting dose42. Folinic acid (Leucovorin, LV) is administered with 5-FU 
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 for biochemical modulation to increase the efficacy and the combination has proven high clinical 
activity in metastatic breast cancer patients43. UFT is administered as a combination of ftorafur 
(tegafur) and uracil at a molar ratio of 1:443.Continuous intravenous infusion of 5-FU is superior 
to bolus injection as increase in exposure to tumor tissues is directly related to tumor response13, 
44. 
Drug sequence 
Irinotecan maximum tolerated dose (MTD) is reached at 300 mg/m2 when irinotecan 
followed 5-FU at 450 mg/m2 when it preceded 5-FU45. Better tolerability is achieved when 
Irinotecan followed by 5-FU sequence is adopted45.  
Drug interaction 
Oxaliplatin-Fluorouracil combination demonstrates synergistic effects with 5-fluoruracil 
(5-FU), even in 5-FU resistant tumors46. 
Pharmacokinetics 
There is lower inter-occasion variability compared to inter-individual variability shows 
promising signs for dose individualization in future courses46. Maximum velocity (Vmax) tends to 
increase with body surface area and the liver metastatic volume of involvement10, 11. Ideal body 
weight (IBW) is selected as a predictor of 5-FU volume of distribution and weight as a predictor 
of 5-FU clearance46.  
Pharmacokinetic model 
5-Fluorouracil (5-FU) disposition is fit by one-compartment model with linear or non-
linear elimination kinetics7, 46,47,48. Disposition of the drug is also best described by two-
compartment model with nonlinear elimination11, 49. 
In one of the studies,  
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 “A four-compartment parent-drug metabolite (5-DHFU) model with nonlinear Michaelis-
Menten elimination from the central compartment of the parent drug (5-FU) is applied to 
describe 5-FU and DHFU pharmacokinetics10”. 
Absorption 
Tegafur is completely and rapidly absorbed after oral administration 9,43,47. Oral UFT/LV 
compares favorably with intravenous 5-FU/LV50. 5-FP (5-Fluoropyrimidonone) is administered 
as an oral prodrug of 5-FU and oral bioavailability of 5FP varies between 78 and 100% 
depending on dosage and dosing regimen8. 
Distribution 
“Vmax tends to increase with body surface area and the liver metastatic volume of    
involvement11”. 
Ideal body weight (IBW) is selected as a predictor of 5-FU Vd46. 
Elimination (Metabolism + Excretion) 
A circadian rhythm following continuous infusion of 5-FU results in diurnal variations in 
clearance, which is due to dihydropyrimidine dehydrogenase activity7. One of the fixed variable 
affecting the clearance is time and modeled as a sum of two cyclic components7. Renal 
impairment causes a moderate and majority increase in the metabolites depending on the 
percentage being excreted in the urine12, 42. Clearance of 5-fluorouracil is significantly reduced 
by increased age and is lower in women compared with men11. Plasma clearance of 5-FU is 
schedule dependent. 5-FU clearance is significantly reduced by increased age, low PMNC-DPD, 
high serum alkaline phosphatase and elapsed time during infusion51. 5-FU undergoes rapid 
hepatic metabolism to give various metabolites with anti-neoplastic properties7.  
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 Metabolism 
Ftorafur gets metabolized slowly in the liver by CYP450. Capecitabine and Ftorafur, both 
utilize the high activity of thymidine phosphorylase in malignant tissue, resulting in a generation 
of 5-FU preferentially in tumor tissue.  
“Capecitabine is first metabolized in the liver to 5’-deoxy-5 fluorocytidine (5’-DFCR) 
which is then converted to 5’-DFUR by cytidine deaminase, principally located in the 
liver and tumor tissue. Further catalytic activation of 5’-DFUR to 5-FU then occurs 
preferentially in the tumor by the tumor-associated angiogenic factor thymidine 
phosphorylase, thereby minimizing the exposure to normal tissues to 5-FU. 
Subsequently, 5-FU is further metabolized to dihydrofluorouracil and then FBAL12”.  
5-FU displays nonlinear pharmacokinetics as a result of saturable metabolism located 
mainly in the liver10, 11,49. As we increase 5-FP dose, there is no corresponding increase in 5-FU, 
which may be due to saturable metabolism of aldehyde oxidase in converting from 5-FP to 5-FU. 
This can be seen from the difference in the extent component (AUC) of the prodrug 5-FP and 
metabolite 5-FU. Uracil acts as an inhibitor of the 5-FU catabolizing enzyme dihydropyrimidine 
dehydrogenase (DPD), resulting in elevated and sustained concentrations of 5-FU in the body. 
DPD is the rate-limiting enzyme of 5-FU and UFT, Eniluracil and S1 are some of the DPD 
inhibiting fluoropyrimidines.  
Excretion 
Renal clearance accounts for 15% of the total body clearance13. Patients with severe and 
moderate renal impairment, the AUC of 5’-DFUR is higher than in patients with normal renal 
function12. 
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 Exposure-Toxicity/Effect relationship 
Toxicities observed are related to gastrointestinal and fatigue8. The most common dose-
limiting toxicity is hand-foot syndrome and in some cases myelosuppression8, 11. Non-
hematological toxicities in patients receiving 5-FU/leucovrin are grade 3 or 4 related adverse 
events diarrhea and stomatitis9, 13,42. Higher incidences of these events are found among patients 
with moderate renal impairment. The most frequently occurring toxicities in the capecitabine 
group are hand-foot syndrome and diarrhea and elderly patients have a higher incidence of grade 
3 or 4 gastrointestinal events42, 52. Dose limiting toxicity is mucositis for continuous infusion and 
myelosuppression for the bolus injection8, 11. Digestive intolerance and oral mucositis are the 
major limiting toxicities during prolonged 5-FU infusions44. Decrease in DPD enzyme activity 
can predispose cancer patients to severe life-threatening toxicity46.  
The maximum tolerated dose is identified as 625 mg/m2/d orally for 5 days every 28 days8. 
Capecitabine when administered in a continuous twice-daily schedule has a maximum tolerated 
dose (MTD) of 828 mg/m2 twice daily13. Hand-foot syndrome, nausea/vomiting, diarrhea, 
neutropenia and abdominal pain are found to limit the capecitabine dose13. Capecitabine is highly 
active compared to 5-FU13. 
 
4.1.3. PLATINUM COMPOUNDS 
4.1.3.1. Cisplatin 
Drug  
Cis-diaminodichloroplatin (CDDP) Cisplatin, Cisplatin is hydrolyzed to monoaqua 
complex53.  
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 Drug indication 
Cisplatin [cis-diamminedichloroplatinum (II), CDDP] is a potent anticancer agent for 
treatment of testicular, bladder, head/neck (H/N), peritoneal carcinoma, ovarian (recurrent) and 
esophageal cancer. Paclitaxel and cisplatin combination chemotherapy is efficacious and feasible 
for an ovarian cancer patient under hemodialysis54. Cisplatin with continuous infusional 5-FU 
and epirubicin (ECF) regimen is used to treat gastrointestinal cancers55. 
Dosage and administration used in various studies 
           Cisplatin dosage is 80 mg/m2 by infusion over 2 h, 3.5 h or 4 h56, 57. Cisplatin dosage 
escalation ranges from 100 to 400 mg/m2 in the case of hyperthermic peritoneal perfusion to 
patients with peritoneal carcinomatosis58. Cisplatin is administered intravenously and dosage 
ranging from 60 to 100 mg/m2 for 90 minutes57, 60. Dosing like any other anti-cancer drug is 
based on body surface area59. 
Time factor and sequence 
          Paclitaxel at a dose of 150 mg/m2 is administered as a 3-h continuous i.v. infusion36. Thirty 
minutes after paclitaxel administration, cisplatin is administered at a dose of 30 mg/m2 for 30 
minutes36. 
Drug interaction 
          Cisplatin-Etoposide (PE) yielded a better response rate compared with cyclophosphamide, 
methotrexate, 5-fluorouracil (CMF) without prior chemotherapy because of the in vivo synergy 
between PE55. In pretreated patients with anthracycline resistant disease, the response rate is 
slightly higher for patients treated with higher doses of cisplatin and docetaxel55. 
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 Pharmacokinetic model 
           Disposition of Cisplatin is described by one-compartment model56. Concentration-time 
data is also described by two-compartment model with an additional peritoneal compartment in 
case of cisplatin peritoneal perfusion57.  
Absorption 
Distribution and binding properties 
The volume of distribution is considerably smaller for the monohydrated complex than 
for cisplatin53. The reason might be cisplatin has more lipophilic property compared to 
monohydrated complex, which mainly stays in the blood53.  
Cisplatin mainly binds to plasma proteins and 95% of cisplatin is protein bound after 24 
hours59. Cisplatin can also bind to RNA and cellular proteins55. Platinum accumulations are 
mostly found in the liver, uterus, testes, ovary and thyroid and the lowest in the brain and 
blood62.  
Elimination 
Clearance of unchanged Cisplatin is affected by dose schedule and body surface area56. 
Regarding dose schedule, the clearance of cisplatin is found to increase after 2-hour infusion 
schedule compared with clearance after longer infusions56. Clearance of filtered platinum is 
significantly related to N-acetyl-β-D-glucosaminidase (urinary enzyme) 60. 
Metabolism 
Excretion 
Exposure-Toxicity/Effect relationship 
Nephrotoxicity, which is the most serious side effect of cisplatin, can be managed using 
sparse data in a clinical setting53, 55, 59, 63. The benefit of peritoneal perfusion is gaining higher 
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 and directy drug exposure to the patients with peritoneal carcinomatosis58. This is shown by 
higher AUC and Cmax by peritoneal perfusion compared to conventional intravenous infusion58. 
Monohydrated complex has also been linked to nephrotoxicity besides cisplatin53. Cisplatin-
Vinblastine combination may alter the severity of neutropenia55. 
4.1.3.2. Carboplatin  
Drug indication 
 
Carboplatin has wide anti-tumor activity with proven efficacy in ovarian cancer, germ cell 
tumors, non-small cell and small-cell lung cancer, head and neck cancer, soft tissue sarcoma, 
urinary tract tumors, breast cancer and brain tumors86.  
Dosage and administration used in various studies 
 
Carboplatin is usually given as single doses in the range 20-500 mg/m2 86.  Carboplatin 
administerd according to body surface area in pediatric patients show large variation in area 
under the curve61.  
“Carboplatin is the only cancer drug for which conventional doses are individually 
adjusted according to estimated clearance and target area under the curve93.” 
Pharmacokinetics 
Carboplatin undergoes dose-independent pharmacokinetics. It is established that the 
pharmacokinetics of carboplatin are linear upto doses of 450 mg/m2. This can be shown by dose-
proportional increases in peak plasma concentration and area under the concentration-time curve 
values and pharmacokinetic parameters of high dose carboplatin agree with those obtained at low 
doses86. 
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 “The unbound plasma carboplatin (fu) could be predicted as a function of time, infusion 
rate and covariates affecting unbound carboplatin clearance, weight, nephrectomy status 
and serum creatinine15”. 
Pharmacokinetic model 
A two-compartment model is used to describe the concentration-time data64, 87. 
Absorption 
Distribution and binding properties 
Weight is a significant covariate on the volume of distribution of the central compartment 
and reflects an increase in physiological or distributional spaces available to unbound carboplatin 
as weight increases15, 86.  The rate of plasma carboplatin binding is low and not dependent on 
patient characteristics89. 
Elimination 
Total body clearance is predicted by Cockcroft and gault formula63. Unbound carboplatin 
clearance is dependent on weight, age, nephrectomy status and serum creatinine15, 86, 87. The 
interindividual vriability in clearance decreased from 74% to 49% by taking account of weight 
and to 29% under the final regression formula62. Carboplatin clearance is significantly related to 
creatinine clearance and body height, explaining 73% of the interindividual variability92. 
Metabolism 
Carboplatin doesn’t undergo appreciative metabolism but is extensively hydrolyzed. 
Excretion 
Renal clearance (primarily due to glomerular filtration) is the major route of excretion with 50-
75% of the urine in 24 h86.  
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 Exposure-Toxicity/Effect relationship 
Myelosuppression, especially thrombocytopenia, is the dose-limiting toxicity of 
carboplatin86.  There is a strong relationship found between the systemic exosure (AUC) of free 
Carboplatin and toxicity (Thrombocytopenia) 88. Ototoxicity is strongly related to the cumulative 
carboplatin AUC90. A sigmoid-maximum effect model describing the relationship between 
thrombocytopenia and free platinum exposure when carboplatin is given along with paclitaxel. 
This shows that the patients experience less thrombocytopenia compared to carboplatin alone91. 
 
4.1.4. TOPOISOMERASE INHIBITORS  
4.1.4.1. Topotecan 
Drug indication 
Topotecan shows activity in human tumor types, including ovarian cancer, non-small cell 
lung cancer (NSCLC), metastatic epithelian ovarian cancer, second-line therapy in patients with 
small cell lung cancer (SCLC) and non-lymphocytic haematologic malignancies. Since the 
topotecan penetrates the CSF, it is used to treat brain tumors17, 65. 
Dosage and administration 
Topotecan is administered intravenous as a 21 day continuous infusion every 28 days16. 
Dosages ranged from 0.4 to 0.6 mg/m2 per day66. Topotecan is administered as 5.5 or 7.5 mg/m2 
per day as a 24-h continuous infusion or 0.5-1.25 mg/m2 per day as a 72-h continuous infusion or 
as 30 minute infusion daily on 5 consecutive days every 3 weeks17. 
Drug interaction 
Amifostine, 300 mg/m2 does not significantly affect the pharmacokinetics of topotecan 
Pharmacokinetics67. 
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 Pharmacokinetics 
Since inter-invidual variability is large compared to inter-occasion variability (6%), there 
is scope for dose individualization68. Inter-patient variability is attributed to differences in organ 
function, serum aspirate aminotransferase and albumin levels and are predictive of topotecan 
pharmacokinetics16. 
Pharmacokinetic model 
The pharmacokinetic profile of topotecan is usually characterized by a two-compartment 
model and is linear in the dose range of 0.5-3.5 mg/m2 69, 70. A three-compartment model 
adequately described topotecan lactone and total concentrations in the plasma and Cerebral 
Spinal Fluid (CSF)17.  
Absorption 
Distribution 
Topotecan is a derivative of campothecin, which has been structurally modified to 
increase water solubility71. 
Elimination 
Elimination of topotecan is independent of the dose70. Topotecan clearance is related to 
serum creatinine level and age72.  
Exposure-Toxicity/Effect relationship 
The main dose-limiting toxicity (DLT) is non-cumulative myelosuppression16. 
4.1.4.2. Etoposide 
Drug indication 
Etoposide (VP16) is widely used in the treatment of patients with a broad variety of solid 
malignancies and hematologic cancers. 
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 Dosage and administration used in various studies 
Oral etoposide is given to children ranging from 25 to 75 mg/m2/day for 21 days72. 
VP16’s efficacy is dose and schedule dependent as drug is more active during the G2 and S 
phases of the cell cycle is usually administered over 3-5 days18, 73. 
Drug interaction 
Cisplatin-Etoposide (PE) yielded a better response rate with cyclophosphamide, 
methotrexate, 5-fluorouracil (CMF) without prior chemotherapy raises the possibility of in vivo 
synergy between Cisplatin-Etoposide combination55. 
Pharmacokinetics 
VP16 displays a mixed renal and hepatic clearance, a high level of protein binding and a 
significant biliary excretion18. These characteristics suggest that small inter-patient or intra-
patient variations in hepatic or renal function may modify VP16 pharmacokinetics behavior and 
subsequent plasma drug exposure18. Etoposide is schedule dependent and the drug is usually 
administered over 3-5 days18. 
Pharmacokinetic model 
Concentration-time profile is best fitted by a three-compartment model after high dose 
Etoposide in children74. A two-compartment open pharmacokinetic model with constant rate i.v. 
infusion, first-order elimination and first-order absorption for patients receiving oral etoposide is 
used to describe the pharmacokinetics of total and unbound etoposide72, 73. 
Absorption 
Etoposide has good oral bioavailability but with substantial inter-individual variation55. 
Exposure to free etoposide during prolonged oral treatment is highly variable among patients75. 
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 This marked inter-individual variability in pharmacokinetics suggests that therapeutic drug 
monitoring might be necessary, especially for oral etoposide18, 73,75. 
Distribution and Binding properties 
Etoposide is highly protein bound and the free etoposide concentration is highly 
correlated with increasing age18, 73,74. Concentration dependent variability among patients in 
binding may occur only at high etoposide levels74.  
Elimination 
Majority of the elimination is associated with β-phase and only fewer percentages 
associated with γ-phase74. Dose normalized for body weight and age of the patient are found to 
have significant correlation with clearance74. A drug interaction is found during doxorubicin and 
cyclophosphamide co-administration affecting biliary elimination76. Co-administration of other 
cytotoxic agents is known to influence etoposide clearance significantly or renal impairment and 
etoposide metabolism74. Etoposide clearance is affected by previous administration of cisplatin, 
which decreases etoposide clearance by three times compared without previous administration of 
cisplatin73.  
Excretion 
Biliary excretion is more significant than metabolism73. 
PK/PD modeling and Exposure-Toxicity relationship 
The dose-limiting toxicity of etoposide is reversible myelosuppression55. Several 
schedules of administration show a correlation between pharmacokinetic parameters of etoposide 
and neutropenia, which represents its main toxicity77. Toxicities included infection, 
cardiotoxicity, myelosuppression, stomatitis and reversible increases in serum creatinine and 
bilirubin19.  
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 4.1.4.3. Irinotecan (CPT11) 
Metabolites: 7-ethyl-10-hydroxycampothecin (SN-38), glucuronic acid conjugate SN-
38G, 7-ethyl-10- [4-N- (5-aminopentanoic acid)-1-piperidino]-carbonyloxycamptothecin 
(Aminopentane carboxylic acid-APC), 7-ethyl-10-[4-amino-1-piperidino] 
carbonyloxycomptothecin (NPC). 
Drug indication 
Colorectal cancer, children with solid tumors 
Dosage and administration used in various studies 
           Dosage and administration of Irinotecan ranges from 100 to 350 mg/m2 and intravenous 
infusion (0.75 to 2.25 h) respectively78, 79. 
Time factor and sequence 
The sequence of treatment with irinotecan and infusional 5-FU affects the tolerability of 
this combination80. Irinotecan MTD is reached at 300 mg/m2 when irinotecan followed 5-FU and 
450 mg/m2 when it preceded 5-FU80. 
Pharmacokinetics 
CPT-11 and SN-38 are found in two forms: lactone and carboxylate78, 81. The inter-
conversion between the lactone and carboxylate forms of CPT-11 is relatively rapid compared to 
SN-3878. SN-38 is excreted or metabolized quickly or is distributed extensively into tissues78. 
Results show that the parent drug and its three major metabolites account for virtually all CPT-
11 disposition, with fecal excretion representing the major elimination pathway20. 
Pharmacokinetic model 
Plasma concentration-time data of irinotecan and its metabolites is described by use of 
two or three compartment models78. A linear four-compartment model is fit simultaneously to 
the IRN, SN-38 and APC lactone plasma concentrations vs. time data81. 
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 Distribution 
The Vss of irinotecan has extensive distribution into the peripheral compartments78. CPT-
11 lactone has extensive tissue distribution compared with carboxylate form78. 
Elimination 
Clearance is higher for the lactone form compared with carboxylate form78.  
Metabolism 
The enzymes involved in CPT-11 metabolism is regulated by pregnane X receptor 
(PXR)79. PXR activation leads to increased biliary excretion of CPT-11 and lowering the 
formation of metabolite SN-38 by reduced of exposure to hepatocytes79. Elderly patients and 
patients with a performance status of 2 are found to have reduced irinotecan clearance79. Sex, 
biliary function, higher total serum bilirubin and genetic variations in the UGT1A1are some of 
the factors affecting SN-38 formation79. 
Excretion 
SN-38G is both non-active and non-toxic and is primarily eliminated by excretion in the 
urine and in bile79. The relatively higher amount of SN-38 in feces compared with bile is 
presumably due to hydrolysis of SN-38G to SN-38 by enteric bacterial beta-glucoronidases20. 
Fecal excretion representing the major elimination pathway20. 
Exposure-Toxicity/Effect relationship 
The major dose-limiting non-hematologic toxicity of irinotecan is diarrhea and is highly 
correlated with SN38G AUC78.  
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 4.2. Population pharmacokinetic models 
4.2.1. 5-fluorouracil 
 
Background 
5-fluorouracil (5-FU) is used in the treatment of colorectal cancer. 5-FU is also used in 
the treatment of advanced gastrointestinal cancer, breast cancer and several other types of cancer. 
5-Fluorouracil (5-FU) dosage is 400 mg/m2 by loading dose and then 600 mg/m2 by continuous 
infusion and folinic acid dosage is 200 mg/m2 administered by intravenous infusion. A circadian 
rhythm following continuous infusion is reported.5-FU is rapidly metabolized by the liver to give 
various metabolites with anti-neoplastic properties. Renal clearance accounts for 15% of the total 
body clearance.There are significant intra- and inter-patient variability in pharmacokinetic 
parameters. Individual 5-FU dose adjustment with pharmacokinetic monitoring provided a high 
survival rate and percentage of responses, with good tolerance. 
Structural model or covariate-free model 
5-FU concentration-time data are fitted by a one-compartment model with linear elimination 
kinetics8. 
)exp( tK
V
DC el ×−×=  
“Data are fitted to a circadian function defined as the sum of two cyclic components of 
12- and 24-h periods respectively: 
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where CLav is the average clearance 
CLA1 and CLA2 the amplitude of the first and the second periodic component, 
respectively 
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 tz1 and tz2 are the acrophase (peak) times of the first and the second periodic components, 
respectively8.” 
Inter-individual variability model 
Volume of the jth subject is described by the relationship: 
)exp( Vjmeanj VV η×=  
where Vmean is the population mean  
           ηVj is the difference in volume of distribution between the population mean and the jth 
subject and ηV is assumed to be a Gaussian random variable with mean zero and variance σ2η. 
)exp( CLjmeanj CLCL η×=  
where CLmean is the population mean and ηCLj is the difference in clearance between the 
population mean and the jth subject; ηCL is assumed to be a Gaussian random variable with mean 
zero and variance σ2η8. 
Covariate model  
21 θθ +×= sexCLmean  
where θ1 and θ2 are model parameters. 
Intra-individual variability model 
The concentration-time profile in the jth individual is assumed to be affected by an additive error 
described by ijε  
ijijjjij tDpftC ε+= ),,()(  
where pj are the pharmacokinetic parameters (clearance, Volume and first-order rate constants) of 
the jth subject,  
tij is the time of the ith measurement 
 Dj is the dosing history of the jth subject, f is the pharmacokinetic model 
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 εij represents the residual departure of the model from the observations and contains contribution 
from intra-individual variability, assay error and model misspecification8. 
Population pharmacokinetic model 
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Population parameters 
 
meanV  = 18.4   
 
Vjη  = 114 
 
1θ  = 60.2 
 
2θ  = 65.0
 
CLjη  = 55.7 
 
ijε  = 0.416 
 
5-Fluorouracil 
Pharmacokinetics of 5-FU is parsimoniously described by a one-compartmental model 
with inter-individual and inter-occassional random effects on clearance only82. A combined 
additive and proportional model best described the pattern of residual error. 
Population pharmacokinetic model 
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Population parameters 
1θ  = 0.907 
 
2θ  = 7.94 
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 CLjη  = 10 
 
3θ  = 15.2 
 
Vjη  = Unestimated 
 
ijε  = 31% 
 
4.2.2. Etoposide (VP16) 
Backgound 
Etoposide is administered by intravenous infusion 40 mg/kg for 4 h. The focus of the 
article is to examine the pharmacokinetics of etoposide with a special focus on terminal 
concentration. 
Low dose Vs. High dose 
There is no significant difference found between the kinetics in adults and children at 
lower doses. However, data on the kinetics in children under high dose conditions are limited. 
Data were best fitted by a three-compartment model after high dose Etoposide in children. 
Significant correlation between clearance, dose normalized for body weight and age of the 
patient was found. Majority of elimination is associated with the β-phase and only fewer 
percentage of elimination is associated with the terminal γ-phase. There is a difference in 
clearance values for high dose etoposide in children compared to high dose etoposide in adults. 
Coadministration of Phenobarbital, known to induce cytochrome P-450 enzymes, may explain 
high CL values. There is high inter-patient and intra-patient variability in the protein binding of 
Etoposide with an increase in unbound drug at high etoposide concentrations. 
Structural model or covariate free model 
Data are best fitted by a three-compartment model after high dose etoposide in children74. 
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 Inter-individual variability model 
)exp( jVVc Vcmeanj η×=  
)exp( 101010 jkmeanj KK η×=  
)exp( 121212 jkmeanj KK η×=  
)exp( 131313 jkmeanj KK η×=  
Intra-individual variability model 
The concentration-time profile in the jth individual is assumed to be affected by an 
exponential error described by the relationship: 
ijijjjij tDpftC ε+= ),,()(  
Population pharmacokinetic model 
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Population parameters 
 
cmeanV  = 0.061  
 
Vη  = 21% 
 
meanK10  = 0.526 
 
jk10η  = 8% 
 
meanK12  = 1.263 
 
jk12η  = 18% 
 
meanK13  = 0.038 
 
jk13η  = 25% 
 
ijε  = 12% 
4.2.3. Topotecan 
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 Background 
Topotecan is used in the treatment of ovarian cancer. The focus of the article is to explore 
inter- and intraindividual variabilities in topotecan clearance using a population pharmacokinetic 
approach. The dose-limiting toxicity of topotecan is myelosuppression, predominantly 
neutropenia. Total Topotecan plasma levels were analyzed according to a two-compartment 
model with linear elimination from the central compartment73. 
The final model with creatinine clearance (CrCl) or that with age and Scr may be useful 
for individual dosing of Topotecan. There is large interoccasion variability between cycle 1 and 
cycle 2 than between days of the same cycle. 
General population pharmacokinetic model is given by 
 
ijpixijfYij ε+= ),(  
 
2)11( εε ++×= CpredCobs  
 
)1( CLjCLmeanCLj η+×=  
 
)1( VcjVcmeanVcj η+×=  
 
)1( VpjVpmeanVpj η+×=  
 
( )( ) ( ) ijijtkk
kkt
Vcj
CLj
Vcj
CLj
Vcj
CLjk
ijVcjweight
DivCij εεββκηθ
++×
⎪⎪⎭
⎪⎪⎬
⎫
⎪⎪⎩
⎪⎪⎨
⎧
×−×−
−+⎟⎟⎠
⎞
⎜⎜⎝
⎛−×
−
−
++×= )1(12exp12
1221exp
21
13
 
 
CrCLCLmean ×= 1θ  for cockcroft-gault formula 
 
WeightVcmean ×= 3θ  
 
4θ=Vpmean  
 
 
Population Parameters 
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 1θ  = 5.47 
 
Vcjη  = 24% 
 
ijκ  = unestimated (non-significant) 
 
3θ  = 0.584 
 
CLjη  = 50% 
 
4θ  = 33.9 
 
Vpjη  = 53% 
 
PE ijε  = 17.1% 
 
AE ijε  = 0.45 
 
4.2.4. E7070 
Structural model or covariate free model 
Data are fit by three-compartment model with saturable transport to the peripheral 
compartment and both linear and saturable elimination from the central compartment72. 
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Inter-individual error model 
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 Covariate model 
])76.1[1( 21 −×+= BSAVcmean θθ  
( )]76.1[1 43max −×+= BSAV mean θθ  
Intraindividual error model 
The concentration-time profile in the jth individual is assumed to be affected by 
combination (additive+exponential) error described by the relationship: 
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Population pharmacokinetic model 
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Population Parameters 
 
1θ  = 6.51 
 
2θ  = 0.646  
 
Vcjη  = 26% 
  
3θ  = 2.55 
 
4θ  = 0.528 
 
jV maxη  = 46% 
 
 = 0.485 mmeanK
 
kmjη  = unestimated 
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 meanT max  = 23.5 
 
jT maxη  = 50% 
 
mmeanT  = 2.25 
 
Tmjη  = 120% 
 
meanjK13  = 0.96  
 
jk13η  = 28% 
 
4.2.5. Cyclophosphamide 
Background 
Cyclophosphamide pharmacokinetics is best described by a one-compartment model82. 
Lower clearance (CL) is found in the second course compared to the first course. Both 
intravenous and oral cyclophosphamide given at conventional doses indicate interoccasion 
variability is not significant. Interindividual variability in clearance is 35% and 21% for 
interoccasion variability. 
Intraindividual error model 
ijpredobs CC ε+= ]ln[]ln[  
Population pharmacokinetic model 
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Population parameters 
1θ  = 70.1 
 
2θ  = 0.907 
 
3θ  = 13.6 
 
CLjη  = 35% 
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 4θ  = 30.1 
 
Vjη  = 14% 
 
PE ijε  = 13% 
 
4.2.6. Methotrexate 
A two-compartmental model is fitted to the Methotrexate pharmacokinetics data with 
inter-individual and inter-occassional random effects on CL, V, Q, and V2 with proportional 
error model best described the pattern of residual error82. 
Inter-individual variability with covariate model 
Pharmacokinetic model 
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Population parameters 
1θ  = 15.5 
 
2θ  = 0.229 
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 Vjη  = 37% 
 
3θ  = 128 
 
4θ  = 1.05 
 
CLjη  = 20% 
 
jk12η  = 28% 
 
jvpη  = 22% 
 
4.2.7. Ifosfamide 
Background 
Ifosfamide (Holoxan) is a prodrug, which needs activation by cytochrome P450-3A4 
(CYP3A4) to 4-hydroxyifosfamide. Ifosfamide metabolites are 2-, 3-dechloroethylifosfamide 
and 4-hydroxyifosfamide. Pharmacokinetics of 4-hydroxyifosfamide are formation rate-limited. 
The Focus of the article is to develop population pharmacokinetic model that describe the 
pharmacokinetics of ifosfamide and its metabolites. Drug indication of this drug is found in 
small-cell lung cancer. Dosage and administration are 2 or 3 g/m2 1-h intravenous infusion over 
1 or 2 days respectively. Ifosfamide active in small cell lung cancer is also effective when added 
with Paclitaxel and Carboplatin as ifosfamides metabolites are able to penetrate the blood-brain 
barrier. Ifosfamide metabolism is subject to autoinduction, which will increase metabolism of 
ifosfamide with time. Considerable interindividual variability was observed in urinary 
recoveries. Both ifosfamide and 4-hydroxyifosfamide exhibited a steeper dose-exposure 
relationship than dechloroethylated metabolites. 
Intra-individual error model 
Ifosfamide concentration-time profiles are adequately modeled by the development of 
autoinduction with an ifosfamide concentration dependent increase in ifosfamide clearance83. 
21)1( εε ++= predobs CC  
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 Inter-individual variability model 
Inter-individual variability of each pharmacokinetic parameter estimated using a 
proportional error model. 
)exp( ipopPPi η×=  where Ppop is the parameter value of a typical individual with η~ N (0,ω2). 
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where R- infusion rate of ifosfamide 
CLinit-initial ifosfamide clearance 
Aenz-relative amount of enzyme in a hypothetical enzyme compartment 
Vifo-volume of distribution 
Autoinduction 
Change in Aenz over time in the enzyme compartment is dependent on Cifo as follows 
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where Kenz, out is the first-order rate constant for enzyme degradation/inactivation. 
IC50 is the ifosfamide concentration at 50% of the maximum inhibition of enzyme degradation. 
The change in the amount of metabolite (Am) over time would be described as  
mm
ifo
ifo
m
m Ak
V
AtCLF
dt
dA ×−××= )(  
where Km is the elimination rate constant of the metabolite. Fm is the fraction of the ifosfamide 
metabolized to the metabolite. 
Population Parameters 
 
initCL  = 2.49 
 
CLinitη  = 41% 
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 ifoV  = 46.2 
 
vifoη  = 17% 
 
ijε  = 17.4% 
 
F*2DCE = 0.0426 
 
DCEF 2*η  = 52% 
 
K2DCE = 2.22 
 
DCEK 2η  = unestimated 
 
ijε  = 6.89 
 
F*3DCE = 0.00771 
 
%363* =DCEFη  
 
K3DCE = 0.138 
 
PE ijε  = 33.1% 
 
AE ijε  = 0.366 
 
F*4OHIF = 0.018 
 
K4OHIF = 9.9 
 
PE ijε  = 30.5% 
 
AE ijε  = 0.218 
 
4.2.8. Nedaplatin 
Background 
Nedaplatin, cis-diammineglycolatoplatinum, is an anticancer agent, which is a platinum 
derivative like cisplatin (CDDP) and carboplatin (CBDCA). Drug indication is found in head 
cancer, neck cancer, nonsmall cell lung carcinoma, oesophagal cancer, testicular tumor and 
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 cervical cancer. Nedaplatin has a short elimination half-life and the platinum clearance is 
predicted based on individual renal function using creatinine clearance after nedaplatin dosing. 
The clinical use of nedaplatin causes less nephrotoxicity, but limiting factor may be its 
hematological toxicity. 
Structural model 
Two-compartment model was fitted to the plasma platinum concentration data84. 
Significant covariates affecting pharmacokinetic parameters: Clearance-Creatinine clearance 
(CLcr calculated by Cockcroft-Gault formula), Vc-Body weight 
Intraindividual error model 
A two-compartment pharmacokinetic model with zero-order input and first order 
elimination is used to describe the data. 
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Pharmacokinetic model 
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 Population pharmacokinetic model 
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Population parameters 
 
1θ  = 4.47 
 
2θ  = 0.0738 
 
CLjη  = 25.5% 
 
3θ  = 12 
 
4θ  = 0.163 
 
Vcjη  = 21.4% 
 
jk12  = 0.304  
 
ijε  = 12.6% 
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 5. CONCLUSION AND DISCUSSION 
 
We achieved the objectives through this work; let us now discuss on the implications of this 
work. We start with the introduction to pharmacokinetics in understanding the need for 
pharmacokinetics in the area of drug development. We apply this understanding to the articles on 
pharmacokinetics by asking relevant questions. This helps us in gathering information from the 
articles. The questions we ask on pharmacokinetics from trials are not objective because of the 
extensiveness of the research in this field. However, we briefly reflect the frequently asked 
questions in chapter 2, section 2. Chapter 3 describes our process of collecting relevant 
biomedical articles by applying a single search criterion and strategy across several National 
Library of Medicine (NLM) service providers. Interestingly, articles collected didn’t overlap 
much and only 20% repeated and this might be partly due to differences in the Medical Subject 
Headings (MeSH). For example, models might fall under biological models in one database and 
mathematical models in another database. The questionnaire helps in the collection of PK 
information from the articles on a particular anti-cancer drug in a structured format. In the future, 
this part may play a pivotal role for scientific researchers and oncologists for future drug 
development utilizing the pre-existing research work. The pre-existing research comprises 
interpretations and possible explanations for pharmacokinetic observations based on biological 
phenomenon. This information was synthesized under sub-headings in chapter 4, section 1 and 
includes dosage and administration, PK processes and models and drug interaction. PK processes 
and models focus mainly on distribution, elimination characteristics and compartmental models 
respectively.       
From statistician point of view, the details in chapter 4, section 2 might be useful for 
stochastic simulation and modeling techniques involved in the formulation of population 
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 pharmacokinetics. The main advantage is to understand the significance of the error models and 
the consequence if assumptions are violated.  
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